MAPT and early-onset autosomal dominant Alzheimer disease: Experimental studies have suggested that the IGF-1 system is beneficial in cognition, especially in Alzheimer’s disease (AD), by opposing Aβ amyloid processing and hyperphosphorylated tau toxicity.